A Phase 1, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-06651600 In Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-06651600 In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs PF 6651600 (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 04 May 2016 Status changed from recruiting to completed.
    • 30 Mar 2016 Planned End Date changed from 1 May 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 30 Mar 2016 Planned primary completion date changed from 1 May 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top